Volume 16, Issue 4 (winter 2009)                   JSSU 2009, 16(4): 92-99 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Owlia M, Mehrpoor G. Rituximab in Adult –Onset Still’s Disease: Case Report. JSSU. 2009; 16 (4) :92-99
URL: http://jssu.ssu.ac.ir/article-1-610-en.html
Abstract:   (6279 Views)
Summary: Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. It is characterized by high grade fever, skin rash, arthritis, leukocytosis, increased ESR, CRP and liver enzyme levels and high levels of ferritin. The treatment of AOSD includes NSAIDs, steroids, and disease-modifying antirheumatic drugs (DMARDs). Recently biologic agents have been used for treatment of some rheumatologic disorders. Rituximab(MabThera), an anti-CD20 monoclonal antibody is one of the biologic agents which is used by only a few researchers for treatment of refractory AOSD. Herein, we describe a 23 year old woman, who was treated with Rituximab ,three years after diagnosis of AOSD .She did not respond to Metotroxate and Cellcept .After administration of Rituximab, clinical and laboratory remission was achieved .
Full-Text [PDF 145 kb]   (3949 Downloads)    
Type of Study: Original article | Subject: General
Received: 2010/01/25

Add your comments about this article : Your username or Email:

© 2018 All Rights Reserved | SSU_Journals

Designed & Developed by : Yektaweb